| 产品描述: | Syk抑制剂;Syk Inhibitors;说明:Entospletinib (GS-9973)是一种口服具有生物活性的,选择性Syk抑制剂,无细胞试验中IC50为7.7 nM。在细胞中,对Syk的选择性比对其他激酶(如Jak2, ckit, Flt3, Ret, KDR)高13-1000倍。;InformationEntospletinib (GS-9973) Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with IC50 of 7.7 nM in a cell-free assay and showed 13- to >1000-fold cellular selectivity for Syk over other kinases(including Jak2, ckit, Flt3, Ret, KDR) as assessed by target protein phosphorylation or functional response.TargetsSyk (Cell-free assay) 7.7 nMIn vitroGS-9973 shows good bidirectional permeability across Caco-2 cell monolayers in vitro. In cells, GS-9973 also shows excellent selectivity for Syk, and potently inhibits BCR-mediated activation and proliferation of B-cells as well as immune-complex-stimulated cytokine production in monocytes. The combination of idelalisib and GS-9973 synergistically inhibits CLL cell viability and further disrupts chemokine signaling.In vivoGS-9973 (1 mg/kg p.o.) shows moderate to high bioavailability in rat and dog. In a rat collagen-induced arthritis model, GS-9973 (1-10 mg/kg p.o.) significantly inhibits ankle inflammation. Moreover, GS-9973 also shows disease-modifying activity in multiple histological measurements, including inhibition of pannus formation, cartilage damage, bone resorption, and peritosteal bone formation with ED50 ranging from 1.2 to 3.9 mg/kg .Cell Research(from reference)Cell lines:MV-4-11 cells Concentrations:~10 μM Incubation Time:72 hours |